Lyra Therapeutics Insiders Still US$66k Away From Original Investment Value [Yahoo! Finance]
Lyra Therapeutics, Inc. (LYRA)
Company Research
Source: Yahoo! Finance
However, the purchase is proving to be an expensive wager as insiders are yet to get ahead of their losses which currently stand at US$66k since the time of purchase. While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares. See our latest analysis for Lyra Therapeutics Lyra Therapeutics Insider Transactions Over The Last Year The Executive Chairman Harlan Waksal made the biggest insider purchase in the last 12 months. That single transaction was for US$74k worth of shares at a price of US$2.96 each. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$0.33). It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel m
Show less
Read more
Impact Snapshot
Event Time:
LYRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYRA alerts
High impacting Lyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LYRA
News
- Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual MeetingsGlobeNewswire
- Lyra Therapeutics, Inc. (NASDAQ: LYRA) was upgraded by analysts at William Blair to a "hold" rating.MarketBeat
- Lyra Therapeutics, Inc. (NASDAQ: LYRA) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.MarketBeat
- Lyra Therapeutics, Inc. (NASDAQ: LYRA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
LYRA
Sec Filings
- 8/15/24 - Form SC
- 8/14/24 - Form 10-Q
- 8/14/24 - Form 8-K
- LYRA's page on the SEC website